On May 3, 2026, the U.S. Food and Drug Administration (FDA) issued a revised New Dietary Ingredient Notification Guidance, mandating DNA barcoding (rbcL & matK) species identification reports—generated by CLIA-certified laboratories—for all plant-derived new dietary ingredients (NDIs). This requirement took effect immediately and directly affects U.S.-bound exports of key Chinese botanical extracts, including green tea extract, ginkgo leaf extract, and curcumin, collectively valued at over USD 800 million annually. Several U.S. importers have already paused acceptance of shipments lacking such reports upon arrival.

Event Overview

The U.S. FDA published the updated New Dietary Ingredient Notification Guidance on May 3, 2026. The revision explicitly requires that all NDI notifications involving plant-sourced ingredients must include a DNA barcoding report confirming species identity using the rbcL and matK gene markers. The report must be issued by a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). This requirement is effective as of May 3, 2026. No further implementation timelines or transitional provisions were announced in the initial release.

Industries Affected

Direct Exporters and Trading Companies

These entities are directly responsible for submitting NDI notifications or supporting documentation to U.S. importers. Without compliant DNA barcoding reports, their products may be rejected at U.S. ports or disallowed from NDI notification review—delaying market access or triggering re-submission requirements.

Raw Material Sourcing and Procurement Firms

Firms sourcing botanical raw materials (e.g., dried leaves, rhizomes, or crude extracts) must now verify species authenticity upstream. Variability in harvest origin, adulteration risk, or mislabeling—previously managed via macroscopic or chemical testing—now carries regulatory consequence due to the mandatory molecular verification step.

Extraction and Manufacturing Facilities

Manufacturers producing standardized extracts must ensure traceability from source material to final product. The new requirement implies tighter integration between botanical authentication (at intake), process documentation, and analytical reporting—potentially necessitating updates to quality agreements and internal SOPs related to identity testing.

Distribution and Import-Related Service Providers

U.S.-based distributors, customs brokers, and regulatory consultants handling NDI submissions or import clearance are now required to validate the presence and validity of CLIA-issued DNA barcoding reports prior to shipment release. Some have already implemented document checkpoints ahead of customs entry.

Key Considerations and Recommended Actions

Monitor official FDA communications for clarifications

Analysis shows the guidance does not specify whether retrospective validation applies to previously submitted NDIs or pending applications. Stakeholders should track FDA’s Q&A updates, webinars, or Federal Register notices for interpretation clarifications—particularly regarding enforcement discretion or acceptable alternative markers.

Prioritize high-volume, high-risk botanical categories

Observably, green tea extract, ginkgo leaf, and curcumin are named in the event summary as categories already impacted by shipment holds. Exporters should treat these as priority cases for immediate alignment with CLIA-qualified labs—and confirm whether batch-level or lot-level reporting is expected.

Distinguish between policy signal and operational implementation

From an industry perspective, the requirement reflects a shift toward molecular authentication as a baseline expectation—not just a best practice. However, actual port-of-entry enforcement (e.g., random document audits vs. universal screening) remains unconfirmed and may evolve gradually.

Prepare upstream documentation and lab coordination workflows

Current more practical steps include: (1) identifying and qualifying CLIA-certified labs capable of rbcL/matK sequencing for target species; (2) updating purchase specifications to require species-verified source materials; and (3) aligning internal QA/QC protocols with the timing and format requirements of DNA report generation.

Editorial Perspective / Industry Observation

Observably, this update signals a formalization—not an introduction—of molecular authentication in U.S. dietary supplement regulation. It elevates DNA barcoding from a voluntary verification tool to a condition of regulatory eligibility for plant-based NDIs. Analysis suggests it functions less as an isolated compliance hurdle and more as a structural reinforcement of the FDA’s focus on ingredient integrity across the supply chain. From an industry standpoint, sustained attention is warranted because the requirement may inform future expectations for other markets (e.g., Canada, ASEAN) and could influence third-party certification standards.

Concluding, this guidance represents a concrete procedural change with immediate operational implications—not merely a policy signal. Its significance lies in the binding linkage between botanical identity verification and market access. It is more appropriately understood as a regulatory threshold now embedded in NDI submission infrastructure, rather than a temporary or advisory measure.

Source: U.S. Food and Drug Administration (FDA), New Dietary Ingredient Notification Guidance, released May 3, 2026.
Note: Enforcement patterns, applicability to legacy NDIs, and potential extensions to non-NDI products remain under observation and are not confirmed in the published guidance.